Total Payments
$1,923
2024 Payments
$246.21
Companies
27
Transactions
102
Medicare Patients
2,943
Medicare Billing
$370,674
Payment Breakdown by Category
Food & Beverage$1,576 (81.9%)
Education$347.15 (18.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,576 | 95 | 81.9% |
| Education | $347.15 | 7 | 18.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $271.54 | 18 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $210.27 | 13 | $0 (2023) |
| Janssen Biotech, Inc. | $189.92 | 8 | $0 (2022) |
| Merck Sharp & Dohme LLC | $178.97 | 7 | $0 (2023) |
| Exelixis Inc. | $140.08 | 4 | $0 (2021) |
| PFIZER INC. | $111.30 | 6 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $108.63 | 7 | $0 (2023) |
| Gilead Sciences, Inc. | $90.85 | 5 | $0 (2024) |
| Celgene Corporation | $85.83 | 4 | $0 (2023) |
| Astellas Pharma US Inc | $70.02 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $246.21 | 11 | PFIZER INC. ($47.03) |
| 2023 | $497.72 | 28 | Novartis Pharmaceuticals Corporation ($144.90) |
| 2022 | $438.80 | 21 | Merck Sharp & Dohme LLC ($135.85) |
| 2021 | $192.84 | 7 | Exelixis Inc. ($123.60) |
| 2020 | $62.50 | 4 | Amgen Inc. ($33.49) |
| 2019 | $139.58 | 10 | E.R. Squibb & Sons, L.L.C. ($26.51) |
| 2018 | $269.55 | 14 | Janssen Biotech, Inc. ($138.43) |
| 2017 | $75.79 | 7 | E.R. Squibb & Sons, L.L.C. ($21.38) |
All Payment Transactions
102 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $25.29 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: NONE | ||||||
| 07/26/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $27.33 | General |
| Category: HEMATOLOGY | ||||||
| 07/22/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.34 | General |
| 07/06/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $22.81 | General |
| Category: Rare Disease | ||||||
| 05/17/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $14.31 | General |
| Category: NONE | ||||||
| 04/18/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: Oncology | ||||||
| 04/01/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $18.11 | General |
| Category: Oncology | ||||||
| 03/02/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $30.91 | General |
| Category: Oncology | ||||||
| 02/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.89 | General |
| 01/26/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, COMIRNATY | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $21.96 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), PIQRAY | Food and Beverage | In-kind items and services | $12.88 | General |
| Category: Oncology | ||||||
| 11/02/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $22.93 | General |
| Category: Hematology | ||||||
| 10/10/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.16 | General |
| Category: Oncology | ||||||
| 10/06/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: ONCOLOGY | ||||||
| 09/29/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug), KISQALI | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: Oncology | ||||||
| 08/28/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: Oncology | ||||||
| 08/11/2023 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: Oncology | ||||||
| 08/08/2023 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: ONCOLOGY | ||||||
| 07/21/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $16.59 | General |
| Category: ONCOLOGY | ||||||
| 07/17/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.47 | General |
| 07/03/2023 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $17.21 | General |
| 06/15/2023 | Genentech USA, Inc. | Lunsumio (Biological), Polivy | Food and Beverage | In-kind items and services | $22.48 | General |
| Category: BioOncology | ||||||
| 05/26/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 644 | 991 | $258,652 | $80,312 |
| 2022 | 7 | 769 | 1,151 | $280,012 | $94,857 |
| 2021 | 7 | 721 | 1,095 | $283,412 | $94,904 |
| 2020 | 7 | 809 | 1,255 | $423,004 | $100,602 |
Total Patients
2,943
Total Services
4,492
Medicare Billing
$370,674
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 281 | 437 | $98,017 | $30,844 | 31.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 88 | 186 | $59,007 | $20,433 | 34.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 32 | 97 | $28,370 | $8,980 | 31.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 135 | 147 | $21,300 | $6,525 | 30.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 36 | 43 | $24,518 | $5,802 | 23.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 47 | 47 | $17,322 | $4,768 | 27.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 11 | 11 | $5,328 | $1,544 | 29.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 23 | $4,790 | $1,415 | 29.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 144 | 316 | $92,083 | $34,939 | 37.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 252 | 365 | $76,649 | $26,362 | 34.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 223 | 257 | $35,127 | $12,127 | 34.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 36 | 98 | $26,922 | $7,576 | 28.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 51 | 51 | $17,352 | $5,234 | 30.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 37 | 38 | $20,290 | $5,177 | 25.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 26 | 26 | $11,589 | $3,442 | 29.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 142 | 395 | $114,155 | $42,728 | 37.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 263 | 332 | $68,060 | $22,161 | 32.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 44 | 52 | $27,248 | $7,822 | 28.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 149 | 162 | $21,546 | $7,003 | 32.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 41 | 41 | $17,999 | $5,786 | 32.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 59 | 59 | $19,824 | $5,424 | 27.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 23 | 54 | $14,580 | $3,980 | 27.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 181 | 436 | $159,738 | $36,391 | 22.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 297 | 360 | $97,600 | $19,958 | 20.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 61 | 173 | $48,376 | $14,023 | 29.0% |
About Dr. Samuel Ofori, M.D
Dr. Samuel Ofori, M.D is a Hematology & Oncology healthcare provider based in Valdosta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548285703.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Samuel Ofori, M.D has received a total of $1,923 in payments from pharmaceutical and medical device companies, with $246.21 received in 2024. These payments were reported across 102 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($1,576).
As a Medicare-enrolled provider, Ofori has provided services to 2,943 Medicare beneficiaries, totaling 4,492 services with total Medicare billing of $370,674. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Hematology
- Location Valdosta, GA
- Active Since 07/12/2006
- Last Updated 06/11/2009
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1548285703
Products in Payments
- KEYTRUDA (Biological) $169.62
- IMBRUVICA (Drug) $138.99
- XTANDI (Drug) $89.05
- PROMACTA (Drug) $82.85
- Pomalyst (Drug) $72.92
- VENCLEXTA (Drug) $67.07
- Neulasta (Biological) $50.52
- ELIQUIS (Drug) $47.89
- Kyprolis (Drug) $46.99
- OPDIVO (Biological) $43.98
- KISQALI (Drug) $43.02
- LUMAKRAS (Drug) $41.47
- XT CDX (Device) $39.09
- DARZALEX (Biological) $36.67
- PIQRAY (Drug) $36.56
- Erleada (Drug) $34.55
- Trodelvy (Drug) $33.15
- Onivyde (Drug) $30.91
- Xtandi (Drug) $29.74
- OXBRYTA (Drug) $27.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.